All articles by Pradeep Bairaboina
Pradeep Bairaboina
Bayer’s elinzanetant receives UK approval for menopause symptoms
The approval is based on successful results from the Phase III OASIS-1, -2, and -3 studies, which evaluated the drug’s efficacy and safety.
AstraZeneca’s Imfinzi gets EU nod for use in bladder cancer treatment
The approval is supported by findings from the NIAGARA Phase III trial, published in The New England Journal of Medicine.
MHRA approves Anktiva for BCG-unresponsive bladder cancer
The drug is administered in combination with BCG via a liquid solution delivered into the bladder through a catheter.
ExCellThera’s Zemcelpro receives positive CHMP opinion for EU market
If approved, Zemcelpro would become the first authorised therapy of its kind in the EU for adults with specific haematological malignancies lacking suitable donor cells.
DoH Abu Dhabi and Sanofi partner to boost global vaccine development
The partnership will focus on streamlining regulatory processes, boosting manufacturing readiness, and encouraging knowledge exchange between local and international experts.
Immuno Cure and PharmaJet announce collaboration to advance a novel HIV therapeutic DNA vaccine using needle-free technology in humans
On June 16, 2025, Immuno Cure and PharmaJet held a material transfer agreement (“MTA”) signing ceremony at the BIO 2025 International Convention in Boston, USA to commemorate such collaboration.
AstraZeneca, China-based CSPC partner to develop novel oral therapies
Under the partnership, both companies will work on pre-clinical candidates targeting chronic diseases, including a small molecule oral therapy for immunological conditions.
GSK and Bharat Biotech collaborate on Shigella vaccine for low-income regions
The partnership aims to advance the development and potential distribution of the vaccine in low- and middle-income countries, where Shigella is a leading cause of diarrhoea among children under five.
Deep Apple, Novo Nordisk sign $812m deal for cardiometabolic drug development
The partnership will leverage Deep Apple’s proprietary drug discovery platform, which integrates machine-learning-driven virtual screening with structural biology facilitated by cryo-electron microscopy.
SpliceBio secures $135m to advance gene therapy for Stargardt disease
The funds will support the clinical development of SpliceBio’s leading gene therapy candidate, SB-007, for Stargardt disease.